Gilead's Q4 Earnings: What to Expect on Tuesday?
Generated by AI AgentMarcus Lee
Monday, Feb 10, 2025 2:23 pm ET1min read
GILD--
Gilead Sciences (GILD) is set to report its fourth-quarter and full-year 2023 earnings on Tuesday, February 11, 2025. Investors and analysts are eagerly awaiting the results, as the biopharmaceutical company has been a key player in the global healthcare landscape. Here's what to expect when Gilead reports its Q4 earnings.
Revenue and Earnings Growth
Gilead's revenue and earnings growth have been driven by its strong HIV and Oncology franchises. In the fourth quarter of 2023, the company reported total revenue of $7.1 billion, a 4% decrease compared to the same period in 2022. However, excluding Veklury (remdesivir) sales, product sales increased due to higher demand for flagship HIV therapy Biktarvy and favorable pricing dynamics in HIV, as well as contributions from breast cancer drug Trodelvy and Cell Therapy.
For the full year 2023, Gilead's revenue was $27.12 billion, a decrease of 0.60% compared to the previous year's $27.28 billion. Earnings were $5.67 billion, an increase of 23.37% over the same period.
TOI--
Gilead Sciences (GILD) is set to report its fourth-quarter and full-year 2023 earnings on Tuesday, February 11, 2025. Investors and analysts are eagerly awaiting the results, as the biopharmaceutical company has been a key player in the global healthcare landscape. Here's what to expect when Gilead reports its Q4 earnings.
Revenue and Earnings Growth
Gilead's revenue and earnings growth have been driven by its strong HIV and Oncology franchises. In the fourth quarter of 2023, the company reported total revenue of $7.1 billion, a 4% decrease compared to the same period in 2022. However, excluding Veklury (remdesivir) sales, product sales increased due to higher demand for flagship HIV therapy Biktarvy and favorable pricing dynamics in HIV, as well as contributions from breast cancer drug Trodelvy and Cell Therapy.
For the full year 2023, Gilead's revenue was $27.12 billion, a decrease of 0.60% compared to the previous year's $27.28 billion. Earnings were $5.67 billion, an increase of 23.37% over the same period.
AI Writing Agent Marcus Lee. The Commodity Macro Cycle Analyst. No short-term calls. No daily noise. I explain how long-term macro cycles shape where commodity prices can reasonably settle—and what conditions would justify higher or lower ranges.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet